Hide metadata

dc.date.accessioned2021-01-31T08:39:11Z
dc.date.available2021-01-31T08:39:11Z
dc.date.created2020-08-31T14:10:23Z
dc.date.issued2020
dc.identifier.citationMagaz, Adrian Ashton, Mark Hathout, Rania Li, Xu Hardy, John Blaker, Jonny J. . Electroresponsive silk-based biohybrid composites for electrochemically controlled growth factor delivery. Pharmaceutics. 2020, 12(8), 1-12
dc.identifier.urihttp://hdl.handle.net/10852/82774
dc.description.abstractStimuli-responsive materials are very attractive candidates for on-demand drug delivery applications. Precise control over therapeutic agents in a local area is particularly enticing to regulate the biological repair process and promote tissue regeneration. Macromolecular therapeutics are difficult to embed for delivery, and achieving controlled release over long-term periods, which is required for tissue repair and regeneration, is challenging. Biohybrid composites incorporating natural biopolymers and electroconductive/active moieties are emerging as functional materials to be used as coatings, implants or scaffolds in regenerative medicine. Here, we report the development of electroresponsive biohybrid composites based on Bombyx mori silkworm fibroin and reduced graphene oxide that are electrostatically loaded with a high-molecular-weight therapeutic (i.e., 26 kDa nerve growth factor-β (NGF-β)). NGF-β-loaded composite films were shown to control the release of the drug over a 10-day period in a pulsatile fashion upon the on/off application of an electrical stimulus. The results shown here pave the way for personalized and biologically responsive scaffolds, coatings and implantable devices to be used in neural tissue engineering applications, and could be translated to other electrically sensitive tissues as well.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleElectroresponsive silk-based biohybrid composites for electrochemically controlled growth factor delivery
dc.typeJournal article
dc.creator.authorMagaz, Adrian
dc.creator.authorAshton, Mark
dc.creator.authorHathout, Rania
dc.creator.authorLi, Xu
dc.creator.authorHardy, John
dc.creator.authorBlaker, Jonny J.
cristin.unitcode185,0,0,0
cristin.unitnameUniversitetet i Oslo
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1826250
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.volume=12&rft.spage=1&rft.date=2020
dc.identifier.jtitlePharmaceutics
dc.identifier.volume12
dc.identifier.issue8
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics12080742
dc.identifier.urnURN:NBN:no-85598
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1999-4923
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/82774/2/Blaker_Electroresponsive_silk_electrochemically_controlled_growth_factor_delivery_Pharmaceutics_2020.pdf
dc.type.versionPublishedVersion
cristin.articleid742


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International